Background To mitigate the effects of COVID-19, a vaccine is urgently needed. BBV152 is a
whole-virion inactivated SARS-CoV-2 vaccine formulated with a toll-like receptor 7/8 agonist …

Background BBV152 is a whole-virion inactivated SARS-CoV-2 vaccine (3 μg or 6 μg)
formulated with a toll-like receptor 7/8 agonist molecule (IMDG) adsorbed to alum (Algel). We …

Background & objectives: Snake-bites are the common cause of morbidity and mortality in
tropical countries. In India, there are 216 species of snakes, of which only four are venomous …

One of the most preferable characteristics for a COVID-19 vaccine candidate is the ability to
reduce transmission and infection of SARS-CoV-2, in addition to disease prevention. Unlike …

We report the development and evaluation of safety and immunogenicity of a whole virion
inactivated (WVI) SARS-CoV-2 vaccine (BBV152), adjuvanted with aluminum hydroxide gel (…

This is a comprehensive report on immunogenicity of COVAXIN ® booster dose against
ancestral and Variants of Concern (VOCs) up to 12 months. It is well known that neutralizing …

Background Despite having milder symptoms than adults, children are still susceptible to
and can transmit SARS-CoV-2. Vaccination across all age groups is therefore necessary to …

IL-12 is a 70-kDa heterodimeric cytokine composed of the p35 and p40 subunits. To maximize
cytokine production from plasmid DNA, molecular steps controlling IL-12p70 biosynthesis …

Background BBV152 is a whole-virion inactivated SARS-CoV-2 vaccine (3 µg or 6 µg)
formulated with a Toll-like receptor 7/8 agonist molecule adsorbed to alum (Algel-IMDG). Earlier, …

Intramuscular injection of macaques with an IL-12 expression plasmid (0.1 or 0.4 mg DNA/animal)
optimized for high level of expression and delivered using in vivo electroporation, …